Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2007-04-17
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C514S337000, C514S338000, C514S339000, C544S326000, C544S328000, C544S405000, C544S408000, C546S277400
Reexamination Certificate
active
10145440
ABSTRACT:
Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II):Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
REFERENCES:
patent: 4296114 (1981-10-01), Appleton et al.
patent: 5223505 (1993-06-01), Hargreaves et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5395817 (1995-03-01), Pallos et al.
patent: 6245769 (2001-06-01), Arvanitis
patent: 4029648 (1992-03-01), None
patent: WO 94/13676 (1994-06-01), None
patent: WO 95/10506 (1995-04-01), None
patent: WO 97/35539 (1997-10-01), None
patent: WO 97/35846 (1997-10-01), None
patent: WO 97/44308 (1997-11-01), None
patent: WO 9744326 (1997-11-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 98/11075 (1998-03-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/11643 (1999-03-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/01675 (2000-01-01), None
patent: WO 00/11003 (2000-03-01), None
Ojea, Vicente; Muinelo, Isabel; Quintela, Jose M., Tetrahedron, 54(5/6), 927-934 (English) 1998.
J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983).
W. Vale et al., Science 213:1394 (1981).
W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983).
G.F. Koob, Persp. Behav. Med. 2:39 (1985).
E.B. DeSouza et al., J. Neurosci. 5:3189 (1985).
J.E. Blalock, Physiological Reviews 69:1 (1989).
J.E. Morley, Life Sci. 41:527 (1987).
E.B. DeSouza, Hosp. Practice 23:59 (1988).
C.B. Nemeroff et al., Science 226:1342 (1984).
C.M. Banki et al., Am. J. Psychiatry 144:873 (1987).
R.D. France et al., Biol. Psychiatry 28:86 (1988).
M. Arato et al., Biol. Psychiatry 25:355 (1989).
C.B. Nemeroff et al., Arch. Gen. Psychiatry 45:577 (1988).
P.W. Gold et al, Am. J. Psychiatry 141:619 (1984).
F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984).
P.W. Gold et al., New Eng. J. Med. 314:1129 (1986).
R.M. Sapolsky, Arch. Gen. Psychiatry 46:1047 (1989).
Grigoriadis et al., Neuropsychopharmacology 2:53 (1989).
D.R. Britton et al., Life Sci. 31:363 (1982).
C.W. Berridge et al., Regul. Peptides 16:83 (1986).
C.W. Berridge et al., Horm. Behav. 21:393 (1987).
Brain Research Reviews 15:71 (1990).
K.T. Britton et al., Psychopharmacology 86:170 (1985).
K.T. Britton et al., Psychopharmacology 94:306 (1988).
N.R. Swerdlow, Psychopharmacology 88:147 (1986).
G.F. Koob et al., Corticotropln-Releasing Factor: Basic and Clinical Studies of a Neuropeptide p. 221 (1990).
C. Maillot et al., Gastroenterology, 119, 1569-1579 (2000).
J.R. McCarthy et al., Curr. Pharm. Res., 5, 289-315 (1999).
P.J. Gilligan et al., J. Med. Chem, 431641-1660 (2000).
G.P. Chrousos, Int. J. Obesity, 24, Supp 2, S50-S55 (2000).
E. Webster et al., Ann. N.Y. Acad. Sci., 840, 21-32 (1998).
D.J. Newport et al., Curr. Opin. Neurobiology, 10, 211-218 (2000).
G. Mastorakos et al., Ann. N.Y. Acad. Sci., 900, 95-106 (2000).
M.J. Owens et al., Expert Opin. Invest. Drugs, 8, 1849-1858 (1999).
G.F. Koob, Ann. N.Y. Acad. Sci., 909, 170-185 (2000).
Remington's Pharmaceutical Sciences, 17thed., Mack Pub. Co, Easton, PA, 1985, p. 1418.
R.C. Larock et al., Tetrahedron Let., 44, 5291 (1987).
Y. Tamura et al., Synthesis, 534 (1981).
Y. Tamura et al., Chem. Pharm. Bull, 32, 1995 (1984).
R.F. Heck et al., Acc. Chem. Res., 12, 146 (1979).
J. Vekemans et al., J. Heterocyclic Chem, 20, 919 (1982).
K. Hirota et al., J. Org. Chem, 57, 5268 (1992).
V. Ratovelomanana et al., Tet. Letters, 52, 6001 (1984).
J. Munson et al., Anal. Biochem., 107:220 (1980).
G. Battaglia et al., Synapse, 1:572 (1987).
Hawley's Condensed Chemical Dictionary (13thed.), J. Wiley & Sons, NY (1997).
Green et al., Protecting Groups in Organic Synthesis, Wiley, NY (1991).
J. March, Advanced Organic Chemistry, Wiley, NY (1992).
The PCT International Search Report dated Sep. 19, 2002 (PCT/US02/15493).
Arvanitis Argyrios G
Gilligan Paul J
Hartz Richard A
Balasubramanian Venkataraman
Bristol-Myers Squibb Pharma Company
Makujina Shah R.
Woodcock & Washburn LLP
LandOfFree
Substituted pyrazinones, pyridines and pyrimidines as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazinones, pyridines and pyrimidines as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazinones, pyridines and pyrimidines as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735953